Mundipharma
Julie Xing is a seasoned executive with extensive experience in leadership roles across the pharmaceutical and biotechnology industries. Currently serving as a Member of the Board of Directors at Aptar and Mars, and as the Executive Chair of China at Mundipharma, Julie brings valuable insights to these prominent organizations. Previously, Julie was the Global Senior Vice President and President of Greater China at Envista Holdings Corporation. Julie's prior experience at Eli Lilly and Company spanned various senior director positions and involved market access and pricing strategy. Additional experience includes leadership roles at Affymetrix and Illumina in the Asia Pacific region. Julie holds a Doctor of Philosophy (Ph.D.) in Biology/Biological Sciences from The Hong Kong University of Science and Technology.
This person is not in any teams
This person is not in any offices
Mundipharma
5 followers
The Mundipharma global network of independent associated companies shares a common purpose to identify and accelerate the development of meaningful medicines that add value for patients and healthcare providers around the globe. Founded in the US by two physicians in 1952 and still privately owned, the network has a presence in over 120 countries. In Europe, the network employees more than 2,000 employees from R&D to manufacturing & supply and commercial, and with revenues in excess of €1 billion. At Mundipharma we strive for one high performing and learning environment where individuals can make a real difference. We have a strong track record of building successful alliances to license, develop and market medicines that improve patients’ lives, while also providing attractive options to financially constrained healthcare systems. Consistent with our entrepreneurial heritage, we like to think that we see what others don’t by challenging conventional wisdom and asking different and challenging questions. By working in partnership with all our stakeholders, the Mundipharma network develops medicines that create value for patients, payers and wider healthcare systems. We have built a European portfolio of medicines to create value for patients, payers and wider healthcare systems across important therapeutic areas such as diabetes, respiratory, oncology, pain and biosimilars.